The global Infection Control and Biosafety Products Market Comprehensive Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments -By Type (Biosafety products, Infection control products), By Application (Children, Adults, Senior Citizens, Foreigners)
In 2024, the market for infection control and biosafety products remains critical as healthcare facilities, laboratories, and public spaces prioritize measures to prevent the spread of infectious diseases and ensure biosafety standards. Infection control and biosafety products encompass a wide range of items, including personal protective equipment (PPE), disinfectants, sterilization equipment, containment devices, and air purification systems, designed to reduce the transmission of pathogens and protect individuals from exposure to infectious agents. With increasing globalization, urbanization, and antimicrobial resistance, the need for effective infection control measures has become more pressing, driving demand for innovative products that offer superior performance, ease of use, and compatibility with existing healthcare protocols. Moreover, the emergence of novel pathogens such as SARS-CoV-2 has accelerated investments in infection control and biosafety products, leading to advancements in technologies such as UV-C disinfection, antimicrobial coatings, and molecular diagnostics for rapid pathogen detection. As healthcare systems and public health agencies continue to prioritize infection prevention and preparedness, the market for infection control and biosafety products is poised for sustained growth and innovation, offering opportunities for product development, regulatory compliance, and collaboration across healthcare, research, and government sectors to address emerging infectious threats and safeguard public health.
The market report analyses the leading companies in the industry including 3M, ABC Compounding, American Biotech Labs, Baxter, Bio-Cide International, BODE Chemie, CareFusion, Ecolab, Hemco Corp, Kewaunee, Labconco, Metrex Research, Reckitt Benckiser Group Plc, STERIS, Terra Universal, The Baker Company, The Clorox Company, Thermo Fisher Scientific, and Others.
The market for infection control and biosafety products is experiencing a prominent trend towards the heightened focus on disease prevention and control, driven by global health concerns, outbreaks of infectious diseases, and the need to mitigate health risks in various settings such as healthcare facilities, laboratories, and public spaces. As governments, healthcare organizations, and businesses prioritize infection control measures to prevent the spread of pathogens and ensure public safety, there is a rising demand for infection control and biosafety products such as personal protective equipment (PPE), disinfectants, sterilization equipment, and containment systems. This trend is fueled by factors such as the emergence of new infectious diseases, increasing antimicrobial resistance, and regulatory requirements for infection control standards, driving market growth and innovation in products designed to safeguard against infectious agents and promote biosafety protocols.
A key driver propelling the market for infection control and biosafety products is the investments in healthcare infrastructure and regulatory compliance initiatives aimed at improving infection prevention and control measures in healthcare facilities and other high-risk environments. As healthcare systems strive to enhance patient safety, reduce healthcare-associated infections, and comply with regulatory guidelines and accreditation standards, there is an increased demand for infection control and biosafety products that meet stringent quality, safety, and performance requirements. This driver is further fueled by government funding, healthcare reform initiatives, and public-private partnerships focused on strengthening healthcare infrastructure and preparedness for infectious disease outbreaks, driving market growth and adoption of infection control solutions that adhere to best practices and standards.
An opportunity exists for manufacturers of infection control and biosafety products to innovate and develop advanced antimicrobial technologies and solutions that offer enhanced efficacy, sustainability, and user-friendliness in preventing the transmission of infectious agents and promoting biosafety practices. By investing in research and development, manufacturers can explore novel antimicrobial agents, surface coatings, and disinfection methods that provide long-lasting protection against a wide range of pathogens, including bacteria, viruses, and fungi. Moreover, leveraging advancements in nanotechnology, UV-C disinfection, and smart sensor technologies can enable the development of next-generation infection control products that offer real-time monitoring, automated disinfection, and data-driven insights for optimizing infection prevention strategies. This opportunity allows manufacturers to differentiate their products in the market, address evolving customer needs and regulatory requirements, and contribute to global efforts to combat infectious diseases and promote biosafety in healthcare and other critical environments.
In the Infection Control and Biosafety Products Market, the segment focused on Infection Control Products is the largest, driven by the critical need to prevent and mitigate the spread of infectious diseases in healthcare settings and beyond. Infection control products encompass a wide range of essential tools and equipment, including disinfectants, sterilization equipment, protective apparel, and hand hygiene products. With the rising prevalence of healthcare-associated infections (HAIs) and the ongoing threat of infectious outbreaks, healthcare facilities prioritize the implementation of robust infection control measures to safeguard patients, healthcare workers, and the community at large. Additionally, the heightened awareness of infection prevention and regulatory mandates further catalyze the demand for infection control products. Further, advancements in technology, such as the development of antimicrobial coatings and automated disinfection systems, enhance the efficacy and efficiency of infection control measures, further bolstering the dominance of this segment in the market. As infection control remains a top priority in healthcare and various other sectors, infection control products continue to play a pivotal role in shaping strategies to combat infectious diseases and ensure biosafety.
Among the segments in the Infection Control and Biosafety Products Market, the segment dedicated to Children is the fastest-growing, driven by the imperative to protect vulnerable populations and address unique infection control challenges associated with pediatric healthcare. Children, especially infants and toddlers, are more susceptible to infections due to their developing immune systems and frequent exposure to communal environments such as schools, daycare centers, and playgrounds. This heightened vulnerability underscores the critical importance of implementing effective infection control measures tailored to the needs of pediatric patients. The growing emphasis on preventive healthcare and the increasing prevalence of pediatric infectious diseases further propel the demand for infection control and biosafety products in pediatric settings. Additionally, innovations in pediatric-specific infection control products, such as child-friendly disinfectants, masks, and hand hygiene solutions, cater to the unique requirements and preferences of pediatric patients and healthcare providers, driving the rapid growth of this segment. As stakeholders prioritize the health and well-being of children, the Children segment emerges as a key driver in shaping the trajectory of the infection control and biosafety products market.
By Type
Biosafety products
Infection control products
By Application
Children
Adults
Senior Citizens
Foreigners
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
3M
ABC Compounding
American Biotech Labs
Baxter
Bio-Cide International
BODE Chemie
CareFusion
Ecolab
Hemco Corp
Kewaunee
Labconco
Metrex Research
Reckitt Benckiser Group Plc
STERIS
Terra Universal
The Baker Company
The Clorox Company
Thermo Fisher Scientific
*- List Not Exhaustive
Chapter 1. TABLE OF CONTENTS
Chapter 2. Introduction to Infection Control and Biosafety Products Market
2.1. Market Overview
2.2. Key Statistics and Report Highlights
2.3. Scope of the Comprehensive Study
2.3.1. Market Definition
2.3.2 Countries and Regions Covered
2.3.3 Research Objective
2.3.4 Units, Currency, and Conversions
2.3.5 Industry Value Chain
2.4. Key Market Segments
2.5. Key Companies
2.6. Study Period
Chapter 3. Strategic Analysis Review
3.1. Infection Control and Biosafety Products Pricing Analysis and Forecast
3.2. Porter’s Five Forces
3.3. Market Ecosystem
3.4. SWOT Analysis
3.5. Regulatory Scenario
3.3. Effects of Inflation, Russia-Ukraine War, moderating economic growth, and other macroeconomic factors
Chapter 4. Competitive Landscape
4.1. Market Share Analysis
4.1.1. Global Infection Control and Biosafety Products Market Share by Company, 2023
4.1.2. Product Offerings of Leading Infection Control and Biosafety Products Companies
4.2. Market Entropy
4.2.1. New Product Launches in the Industry
4.2.2. Mergers, Acquisitions, Joint ventures, and Partnerships
4.3. Key Strategies and Best Practices
Chapter 5. Global Market Projections: Best, Reference, and Low Case Scenarios
5.1. Growth Analysis- Case Scenario Definitions
5.2. Low Growth Case Scenario Forecasts
5.3. Reference Growth Case Scenario Forecasts
5.4. High Growth Case Scenario Forecasts
Chapter 6. Market Dynamics
6.1. Infection Control and Biosafety Products Market Drivers
6.2. Infection Control and Biosafety Products Market Challenges
6.6. Infection Control and Biosafety Products Market Opportunities
6.4. Infection Control and Biosafety Products Market Trends
Chapter 7. Global Infection Control and Biosafety Products Market Outlook Trends
7.1. Global Infection Control and Biosafety Products Revenue (USD Million) and CAGR (%) by Type (2021-2032)
7.2. Global Infection Control and Biosafety Products Revenue (USD Million) and CAGR (%) by Application (2021-2032)
7.3. Global Infection Control and Biosafety Products Revenue (USD Million) and CAGR (%) by Product (2021-2032)
By Type
Biosafety products
Infection control products
By Application
Children
Adults
Senior Citizens
Foreigners
Chapter 8. Global Infection Control and Biosafety Products Regional Analysis and Outlook
8.1. Global Infection Control and Biosafety Products Revenue (USD Million) By Regions (2021- 2032)
8.2. North America Infection Control and Biosafety Products Revenue (USD Million) by Country (2021-2032)
8.2.1. United States Infection Control and Biosafety Products Regional Analysis and Outlook
8.2.2. Canada Infection Control and Biosafety Products Regional Analysis and Outlook
8.2.3. Mexico Infection Control and Biosafety Products Regional Analysis and Outlook
8.3. Europe Infection Control and Biosafety Products Revenue (USD Million), by Country (2021-2032)
8.3.1. Germany Infection Control and Biosafety Products Regional Analysis and Outlook
8.3.2. France Infection Control and Biosafety Products Regional Analysis and Outlook
8.3.3. United Kingdom Infection Control and Biosafety Products Regional Analysis and Outlook
8.3.4. Spain Infection Control and Biosafety Products Regional Analysis and Outlook
8.3.5. Italy Infection Control and Biosafety Products Regional Analysis and Outlook
8.3.6. Russia Infection Control and Biosafety Products Regional Analysis and Outlook
8.3.7. Rest of Europe Infection Control and Biosafety Products Regional Analysis and Outlook
8.4. Asia Pacific Infection Control and Biosafety Products Revenue (USD Million) by Country (2021-2032)
8.4.1. China Infection Control and Biosafety Products Regional Analysis and Outlook
8.4.2. Japan Infection Control and Biosafety Products Regional Analysis and Outlook
8.4.3. India Infection Control and Biosafety Products Regional Analysis and Outlook
8.4.4. South Korea Infection Control and Biosafety Products Regional Analysis and Outlook
8.4.5. Australia Infection Control and Biosafety Products Regional Analysis and Outlook
8.4.6. South East Asia Infection Control and Biosafety Products Regional Analysis and Outlook
8.4.7. Rest of Asia Pacific Infection Control and Biosafety Products Regional Analysis and Outlook
8.5. South America Infection Control and Biosafety Products Revenue (USD Million), by Country (2021-2032)
8.5.1. Brazil Infection Control and Biosafety Products Regional Analysis and Outlook
8.5.2. Argentina Infection Control and Biosafety Products Regional Analysis and Outlook
8.5.3. Rest of South America Infection Control and Biosafety Products Regional Analysis and Outlook
8.6. Middle East and Africa Infection Control and Biosafety Products Revenue (USD Million) by Country (2021-2032)
8.6.1. Middle East Infection Control and Biosafety Products Regional Analysis and Outlook
8.6.2. Africa Infection Control and Biosafety Products Regional Analysis and Outlook
Chapter 9. North America Infection Control and Biosafety Products Analysis and Outlook
9.1. North America Infection Control and Biosafety Products Revenue (USD Million) by Segments (2021-2032)
9.1.1. North America Infection Control and Biosafety Products Revenue (USD Million) by Type (2021-2032)
9.1.2. North America Infection Control and Biosafety Products Revenue (USD Million) by Application (2021-2032)
9.1.3. North America Infection Control and Biosafety Products Revenue (USD Million) by Product (2021-2032)
By Type
Biosafety products
Infection control products
By Application
Children
Adults
Senior Citizens
Foreigners
Chapter 10. Europe Infection Control and Biosafety Products Analysis and Outlook
10.1. Europe Infection Control and Biosafety Products Revenue (USD Million), by Segments (USD Million) (2021-2032)
10.1.1. Europe Infection Control and Biosafety Products Revenue (USD Million) by Type (2021-2032)
10.1.2. Europe Infection Control and Biosafety Products Revenue (USD Million) by Application (2021-2032)
10.1.3. Europe Infection Control and Biosafety Products Revenue (USD Million) by Product (2021-2032)
By Type
Biosafety products
Infection control products
By Application
Children
Adults
Senior Citizens
Foreigners
Chapter 11. Asia Pacific Infection Control and Biosafety Products Analysis and Outlook
11.1. Asia Pacific Infection Control and Biosafety Products Revenue (USD Million), and Revenue (USD Million) by Segments (2021-2032)
11.1.1. Asia Pacific Infection Control and Biosafety Products Revenue (USD Million) by Type (2021-2032)
11.1.2. Asia Pacific Infection Control and Biosafety Products Revenue (USD Million) by Application (2021-2032)
11.1.3. Asia Pacific Infection Control and Biosafety Products Revenue (USD Million) by Product (2021-2032)
By Type
Biosafety products
Infection control products
By Application
Children
Adults
Senior Citizens
Foreigners
Chapter 12. South America Infection Control and Biosafety Products Analysis and Outlook
12.1. South America Infection Control and Biosafety Products Revenue (USD Million), by Segments (2021-2032)
12.1.1. South America Infection Control and Biosafety Products Revenue (USD Million) by Type (2021-2032)
12.1.2. South America Infection Control and Biosafety Products Revenue (USD Million) by Application (2021-2032)
12.1.3. South America Infection Control and Biosafety Products Revenue (USD Million) by Product (2021-2032)
By Type
Biosafety products
Infection control products
By Application
Children
Adults
Senior Citizens
Foreigners
Chapter 13. Middle East and Africa Infection Control and Biosafety Products Analysis and Outlook
13.1. Middle East and Africa Infection Control and Biosafety Products Revenue (USD Million), by Segments (2021-2032)
13.1.1. Middle East and Africa Infection Control and Biosafety Products Revenue (USD Million) by Type (2021-2032)
13.1.2. Middle East and Africa Infection Control and Biosafety Products Revenue (USD Million) by Application (2021-2032)
13.1.3. Middle East and Africa Infection Control and Biosafety Products Revenue (USD Million) by Product (2021-2032)
By Type
Biosafety products
Infection control products
By Application
Children
Adults
Senior Citizens
Foreigners
Chapter 14. Infection Control and Biosafety Products Company Profiles
14.1 Business Overview
14.2 Product Profiles
14.3 SWOT Profiles
14.5 Recent Developments
14.6 Financial Profile
List of Companies
3M
ABC Compounding
American Biotech Labs
Baxter
Bio-Cide International
BODE Chemie
CareFusion
Ecolab
Hemco Corp
Kewaunee
Labconco
Metrex Research
Reckitt Benckiser Group Plc
STERIS
Terra Universal
The Baker Company
The Clorox Company
Thermo Fisher Scientific
15. Methodology and Data Sources
15.1 Customization Offerings
15.2 Subscription Services
15.3 Related Reports
15.4 Publisher Expertise
LIST OF TABLES
Table 1 Market Segmentation Analysis
Table 2 Global Infection Control and Biosafety Products Market Share of Leading Companies, 2023
Table 3 Product Offerings of Leading Companies
Table 4 Low Growth Scenario Forecasts
Table 5 Reference Case Growth Scenario
Table 6 High Growth Case Scenario
Table 7 Global Infection Control and Biosafety Products Revenue (USD Million) And CAGR (%) By Type (2021-2032)
Table 8 Global Infection Control and Biosafety Products Revenue (USD Million) And CAGR (%) By Application (2021-2032)
Table 9 Global Infection Control and Biosafety Products Revenue (USD Million) And CAGR (%) By Product (2021-2032)
Table 10 Global Infection Control and Biosafety Products Market Revenue (USD Million) By Regions (2021-2032)
Table 11 Global Infection Control and Biosafety Products Market Share (%) By Regions (2021-2032)
Table 12 North America Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Table 13 Europe Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Table 14 Asia Pacific Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Table 15 South America Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Table 16 Middle East and Africa Infection Control and Biosafety Products Revenue (USD Million) By Region (2021-2032)
Table 17 North America Infection Control and Biosafety Products Revenue (USD Million) By Type (2021-2032)
Table 18 North America Infection Control and Biosafety Products Revenue (USD Million) By Application (2021-2032)
Table 19 North America Infection Control and Biosafety Products Revenue (USD Million) By Product (2021-2032)
Table 20 Europe Infection Control and Biosafety Products Revenue (USD Million) By Type (2021-2032)
Table 21 Europe Infection Control and Biosafety Products Revenue (USD Million) By Application (2021-2032)
Table 22 Europe Infection Control and Biosafety Products Revenue (USD Million) By Product (2021-2032)
Table 23 Asia Pacific Infection Control and Biosafety Products Revenue (USD Million) By Type (2021-2032)
Table 24 Asia Pacific Infection Control and Biosafety Products Revenue (USD Million) By Application (2021-2032)
Table 25 Asia Pacific Infection Control and Biosafety Products Revenue (USD Million) By Product (2021-2032)
Table 26 South America Infection Control and Biosafety Products Revenue (USD Million) By Type (2021-2032)
Table 27 South America Infection Control and Biosafety Products Revenue (USD Million) By Application (2021-2032)
Table 28 South America Infection Control and Biosafety Products Revenue (USD Million) By Product (2021-2032)
Table 29 Middle East and Africa Infection Control and Biosafety Products Revenue (USD Million) By Type (2021-2032)
Table 30 Middle East and Africa Infection Control and Biosafety Products Revenue (USD Million) By Application (2021-2032)
Table 31 Middle East and Africa Infection Control and Biosafety Products Revenue (USD Million) By Product (2021-2032)
LIST OF FIGURES
Figure 1. Market Scope
Figure 2. Pricing Forecasts Per Unit, 2023- 2032
Figure 3. Porter’s Five Forces
Figure 4. Global Infection Control and Biosafety Products Market Revenue (USD Million) By Regions (2021-2032)
Figure 5. Global Infection Control and Biosafety Products Market Share (%) By Regions (2023)
Figure 6. North America Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 7. United States Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 8. Canada Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 9. Mexico Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 10. Europe Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 11. Germany Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 12. France Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 13. United Kingdom Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 14. Spain Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 15. Italy Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 16. Russia Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 17. Rest of Europe Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 11. Asia Pacific Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 12. China Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 13. Japan Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 14. India Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 15. South Korea Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 16. Australia Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 17. South East Asia Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 18. South America Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 19. Brazil Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 20. Argentina Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 21. Rest of Asia Pacific Infection Control and Biosafety Products Revenue (USD Million) By Country (2021-2032)
Figure 22. Middle East and Africa Infection Control and Biosafety Products Revenue (USD Million) By Region (2021-2032)
Figure 23. Saudi Arabia Infection Control and Biosafety Products Revenue (USD Million) By Region (2021-2032)
Figure 24. The UAE Infection Control and Biosafety Products Revenue (USD Million) By Region (2021-2032)
Figure 25. Rest of Middle East Infection Control and Biosafety Products Revenue (USD Million) By Region (2021-2032)
Figure 26. South Africa Infection Control and Biosafety Products Revenue (USD Million) By Region (2021-2032)
Figure 27. Africa Infection Control and Biosafety Products Revenue (USD Million) By Region (2021-2032)
Figure 28. North America Infection Control and Biosafety Products Revenue (USD Million) By Type (2021-2032)
Figure 29. North America Infection Control and Biosafety Products Revenue (USD Million) By Application (2021-2032)
Figure 30. North America Infection Control and Biosafety Products Revenue (USD Million) By Product (2021-2032)
Figure 31. Europe Infection Control and Biosafety Products Revenue (USD Million) By Type (2021-2032)
Figure 32. Europe Infection Control and Biosafety Products Revenue (USD Million) By Application (2021-2032)
Figure 33. Europe Infection Control and Biosafety Products Revenue (USD Million) By Product (2021-2032)
Figure 34. Asia Pacific Infection Control and Biosafety Products Revenue (USD Million) By Type (2021-2032)
Figure 35. Asia Pacific Infection Control and Biosafety Products Revenue (USD Million) By Application (2021-2032)
Figure 36. Asia Pacific Infection Control and Biosafety Products Revenue (USD Million) By Product (2021-2032)
Figure 37. South America Infection Control and Biosafety Products Revenue (USD Million) By Type (2021-2032)
Figure 38. South America Infection Control and Biosafety Products Revenue (USD Million) By Application (2021-2032)
Figure 39. South America Infection Control and Biosafety Products Revenue (USD Million) By Product (2021-2032)
Figure 40. Middle East and Africa Infection Control and Biosafety Products Revenue (USD Million) By Type (2021-2032)
Figure 41. Middle East and Africa Infection Control and Biosafety Products Revenue (USD Million) By Application (2021-2032)
Figure 42. Middle East and Africa Infection Control and Biosafety Products Revenue (USD Million) By Product (2021-2032)
By Type
Biosafety products
Infection control products
By Application
Children
Adults
Senior Citizens
Foreigners
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Global Infection Control and Biosafety Products Market Size is valued at $54.2 Billion in 2024 and is forecast to register a growth rate (CAGR) of 8.2% to reach $101.8 Billion by 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
3M, ABC Compounding, American Biotech Labs, Baxter, Bio-Cide International, BODE Chemie, CareFusion, Ecolab, Hemco Corp, Kewaunee, Labconco, Metrex Research, Reckitt Benckiser Group Plc, STERIS, Terra Universal, The Baker Company, The Clorox Company, Thermo Fisher Scientific
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2032; Currency: Revenue (USD); Volume